Business Wire

SoftBank Group to Acquire Ampere Computing

20.3.2025 00:30:00 CET | Business Wire | Press release

Share

SoftBank Group Corp. (TSE: 9984, “SoftBank Group”) today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere’s lead investors – Carlyle (NASDAQ: CG) and Oracle Corp. (NYSE: ORCL) – are selling their respective positions in Ampere.

As SoftBank Group broadens its AI infrastructure investments in ventures such as Cristal intelligence and Stargate, the acquisition will help enhance SoftBank Group’s capabilities in key areas and accelerate its growth initiatives.

“The future of Artificial Super Intelligence requires breakthrough computing power,” said Masayoshi Son, Chairman and CEO of SoftBank Group Corp. “Ampere’s expertise in semiconductors and high-performance computing will help accelerate this vision, and deepens our commitment to AI innovation in the United States.”

“With a shared vision for advancing AI, we are excited to join SoftBank Group and partner with its portfolio of leading technology companies,” said Renee James, Founder and CEO of Ampere. “This is a fantastic outcome for our team, and we are excited to drive forward our AmpereOne® roadmap for high performance Arm processors and AI.”

Founded in Silicon Valley in 2018 with an initial focus on cloud-native computing, Ampere has since expanded into sustainable AI compute. The company has multiple products for a spectrum of cloud workloads from the edge to the cloud data center.

Transaction Details
Under the terms of the agreement, SoftBank will acquire Ampere for $6.5 billion in cash. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the second half of 2025. Ampere’s headquarters will remain in Santa Clara, CA.

About SoftBank Group
The SoftBank Group invests in breakthrough technology to improve the quality of life for people around the world. The SoftBank Group is comprised of SoftBank Group Corp. (TOKYO: 9984), an investment holding company that includes stakes in AI, smart robotics, IoT, telecommunications, internet services, and clean energy technology providers, as well as a majority stake in Arm, which is building the future of computing; and the SoftBank Vision Funds, which are investing to help transform industries and shape new ones. To learn more, please visit https://group.softbank/en.

About Ampere
Ampere is a semiconductor design company focused on high-performance, energy efficient, sustainable AI Compute based on the Arm compute platform. To learn more, please visit https://amperecomputing.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250319660334/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 15:02:00 CEST | Press release

Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratificationPresentations reflect Guardant’s strong biopharma and academic collaborations, along with public-private partnerships in Europe Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators

First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 15:00:00 CEST | Press release

Light jet combines next-generation capability, pilot-focused innovation and added customer confidence to every mission. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said

ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 14:00:00 CEST | Press release

Process Context for Enterprise AI provides vital business understanding for the AI ecosystem – helping enterprises unlock greater AI value, fasterNew capabilities improve operational performance, identify where AI can deliver the most value and give agents access to trusted process contextCombines Object-Centric Process Mining (OCPM), Process Lens and Model Context Protocol (MCP) to create essential platform for agentic AI at scale ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehen

Visa, BILL and Billtrust Launch First Live Pilot for Trusted AI Agent Payments Between Buyer and Supplier Platforms20.10.2026 14:00:00 CEST | Press release

Demonstrates how trusted AI agents are moving beyond automation to act on behalf of buyers and suppliers in real-world commercial transactions. Visa (NYSE: V), BILL (NYSE: BILL) and Billtrust today announced they have launched the first live pilot to enable trusted AI agents to initiate and complete approved buyer invoice payments end-to-end through supplier portals. Until now, many payment portals relied on human authentication requirements that limited how approved payments could be automated. Together, with leading accounts payable and receivable solutions providers BILL and Billtrust, the Visa Intelligent CommerceTM portfolio helps bridge that gap. Leveraging offerings such as Visa Trusted Agent Protocol, AI agents can now be securely authenticated to credentialed portals. As a result, buyer payments that previously relied on manual entry can be completed by trusted AI agents, while preserving supplier control and oversight. How trusted AI agents are overcoming one of payment autom

Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility20.10.2026 14:00:00 CEST | Press release

New modular platform gives researchers greater control over sample and cell throughput while optimizing value Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overall cost. Evercode MAX enables researchers to build a kit configuration around their experiment, with sample barcoding and library preparation as independent kits. Evercode MAX is available for Whole Transcriptome, WT FFPE, TCR, BCR, and CRISPR Detect. With configurations supporting up to 384 samples and 2 million cells, researchers can prioritize more samples to characterize biological variation or more cells per s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye